Terms ending in 2043
Every in-force patent on Lifeedit, Inc.'s record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,398,385 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence | |
| US 12,435,325 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence | |
| US 12,473,539 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence | |
| US 12,624,369 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence | |
| US 12,680,096 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.